Pyrazole Carboxamide TAAR1 Modulators for Selective CNS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medications targeting central nervous system disorders often have undesirable side effects due to non-selectivity for trace amine associated receptors (TAARs) over adrenergic receptors, and there is a need for compounds that effectively target TAAR1 for treating various psychiatric and neurological conditions.
Innovation Solution
Development of specific compounds of formula I, which are racemic mixtures, enantiomers, and optical isomers, and their pharmaceutically acceptable salts, exhibiting selectivity for TAAR1 receptors, particularly TAAR1, to treat depression, anxiety disorders, Parkinson's disease, and other conditions by binding to trace amine associated receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to target adrenergic receptors for treating CNS disorders, then therapeutic effects are achieved, but undesirable side effects occur due to non-selectivity
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (formula I featuring pyrazole carboxamide with particular substituent patterns) that confer selective affinity for TAAR1 receptors while reducing interaction with adrenergic receptors. This structural differentiation creates localized binding preferences that achieve therapeutic effects on target receptors while minimizing off-target side effects.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types (R1, R2, R3 groups), their positions, and stereochemical configurations to optimize receptor selectivity. By adjusting these chemical parameters, the compounds achieve enhanced TAAR1 binding affinity while maintaining reduced adrenergic receptor interaction, thereby improving the therapeutic index.
2Object-affected harmful factors
If compounds are designed to be highly selective for TAAR1 receptors, then side effects are reduced, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments (pyrazole core, carboxamide linkage, and variable substituent groups R1-R6) that can be independently optimized. This modular approach allows systematic exploration of structure-activity relationships by varying individual segments while maintaining the core pharmacophore, thereby managing development complexity through organized molecular design.
Solution Approach 2:
The patent employs universality by creating a versatile molecular scaffold (formula I) that can accommodate multiple substituent variations while maintaining TAAR1 selectivity. This universal framework enables the development of a series of related compounds with different pharmacokinetic properties from a single core structure, reducing overall development complexity by reusing the validated pharmacophore across multiple derivatives.
Data Source
AI summary
The present invention relates to compounds of formula (I) wherein R1 is phenyl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkoxy, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, lower alkoxy substituted by halogen or lower alkoxy substituted by hydroxy; or is pyridine-2, 3 or 4-yl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, cyano, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy, lower alkoxy, lower alkoxy substituted by halogen or lower alkoxy substituted by hydroxyl; or is pyrimidin-2, 4 or 5-yl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkyl substituted by hydroxy or lower alkyl substituted by halogen; or is pyrazin-2-yl, optionally substituted by halogen, lower alkyl, lower cycloalkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy or cyano; or is 2,2-difluorobenzo[d][l,3]dioxol-5-yl, or is thiazolyl, optionally substituted by lower alkyl substituted by halogen; R2 is hydrogen or lower alkyl; R3 is hydrogen, amino or lower alkyl; Z is a bond, -CH2- or -O-; or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formulas I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.